Loading organizations...

§ Private Profile · Paris, Ile-de-France, France
Develops point-of-care molecular diagnostic kits with aptamer technology for infectious diseases, targeting Lyme disease.
Based in Paris, France, En Carta Diagnostics develops rapid point-of-care molecular diagnostic kits utilizing synthetic biology and patented aptamer technology to detect infectious diseases without requiring external power sources. The company's programmable platform initially targets early Lyme disease diagnosis, with the capacity to adapt for additional pathogens such as Zika, malaria, and Ebola. Operating with a team of one to ten employees, the startup has built five prototypes and published ten scientific papers, while its scientific team also secured a $17.7 million research award from DARPA. In May 2024, the enterprise raised €1.5 million in pre-seed funding led by CentraleSupélec Venture to advance its preclinical data, supported by strategic advisors including CVS Health board member Jean-Pierre Millon. En Carta Diagnostics was founded in 2022 by Guillaume Horréard, Margot Karlikow, Alex Green, and Keith Pardee.
En Carta Diagnostics has raised $1.6M across 1 funding round.
En Carta Diagnostics has raised $1.6M in total across 1 funding round.
En Carta Diagnostics has raised $1.6M across 1 funding round. Most recently, it raised $1.6M Pre-Seed in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 22, 2024 | $1.6M Pre Seed | Cédric Curtil | — | Announced |
En Carta Diagnostics has raised $1.6M in total across 1 funding round.
En Carta Diagnostics's investors include Cédric Curtil.